Routine plasma anti-XA monitoring is required for low-molecular-weight heparins

Clinical Pharmacokinetics

Volumn 49, Issue 9, 2010, Pages 567-571

  Al Sallami, Hesham S ^a   Barras, Michael A ^b   Green, Bruce ^c   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Mater Health Services   (Australia)

^c Model Answers Pty Ltd   (Australia)

Author keywords

antithrombotics; dose prediction; drug monitoring; enoxaparin sodium; factor xa inhibitors; low molecular weight heparins; pharmacokinetic modelling.; pharmacokinetics

Indexed keywords

ENOXAPARIN; HEPARIN;

ACCURACY; BLEEDING; CREATININE CLEARANCE; DRUG MONITORING; NOTE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RISK FACTOR; SIMULATION;

ANTICOAGULANTS; DRUG MONITORING; ENOXAPARIN; FACTOR XA; HEPARIN; HUMANS; MOLECULAR WEIGHT;

EID: 77955437954     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11532960-000000000-00000     Document Type: Note

References (21)

1. Magee KD, Sevcik W, Moher D, et al. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst Rev 2003; (1): CD002132
2. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007 Sep; 28 (17): 2077-2086
3. van Dongen CJ, van den Belt AG, Prins MH, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; (4): CD001100
4. Turpie AG. Successors to heparin: new antithrombotic agents. Am Heart J 1997 Nov; 134 (5 Pt 2): S71-7
5. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001 Jan; 119 (1 Suppl.): 64S-94S
6. Antman EM, McCabe CH, Gurfinkel EP, etal. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999 Oct 12; 100 (15): 1593-1601
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997 Aug 14; 337 (7): 447-452
8. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003 Jul; 56 (1): 96-103
9. Green B, Greenwood M, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005 Mar; 59 (3): 281-290
10. Begg EJ, Barclay ML. Aminoglycosides: 50 years on. Br J Clin Pharmacol 1995 Jun; 39 (6): 597-603
11. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 188S-203S (Pubitemid 39297954)
12. Sanofi-Aventis New Zealand Limited. Clexane® and Clexane® Forte: data sheet. Auckland: Sanofi-Aventis New Zealand Limited, 2010 Apr 13 [online]. Available from URL: http://medsafe.govt.nz/profs/Datasheet/c/Clexaneinj. pdf [Accessed 2010 May 25]
13. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 1997 Jun; 29 (7): 1474-1482
14. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to sur-vival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004 Jul 27; 110 (4): 392-398
15. Barras MA, Duffull SB, Atherton JJ, et al. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther 2008 Jun; 83 (6): 882-888
16. Giugliano RP, Rohatagi S, Kastrissios H, et al. The relationship between oral factor Xa (FXa) inhibitor DU-176b pharmacokinetics (PK) and the probability of bleeding events (BE) in patients with atrial fibrillation (AF) [abstract no. OC-WE-003]. XXII Congress, International Society on Thrombosis and Haemostasis; 2009 Jul 11-16; Boston (MA) [online]. Available from URL: http://abstract.mci- group.com/cgi-bin/mc/printabs.pl?APP=ISTH2009ABS-abstract&TEMPLATE= &keyf=2790&showHide=show&client= [Accessed 2010 May 25]
17. Mungall D, Floyd R. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol 1989 Nov; 29 (11): 1043-1047
18. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004 Jul 7; 292 (1): 89-96 (Pubitemid 38923799)
19. Ward ML, Duffull SB. Experience with heparin dosing at Christchurch Hos-pital. N Z Med J 1998 Jun 26; 111 (1068): 228-230
20. Burton ME, Vasko MR, Brater DC. Comparison of drug dosing methods. Clin Pharmacokinet 1985 Jan-Feb; 10 (1): 1-37
21. Duffull SB, van den Berg L, Kirkpatrick C. TCIWorks: target concentration intervention software [online]. Available from URL: http://www.tciworks. info [Accessed 2010 May 25]